A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Exclusion Criteria

• •QT interval corrected for heart rate (QTc) using Fridericia's correction of \> 470 msec (females) or \> 450 msec (males), Grade 3 arrythmia, and/or other clinically significant cardiac abnormalities.
• •Known to be B-cell leukemia/lymphoma 2 inhibitor (BCL-2i) refractory or has received a BCL-2i-containing regimen within (6 months) of starting study drug (e.g., venetoclax, lisaftoclax, BGV-11417).
• •Has active human immunodeficiency virus (HIV) infection. HIV testing is not required unless required locally.
• •Recent history (within 6 months) of:
• •* Congestive heart failure (defined as New York Heart Association, Class 2 or higher).
• •* Ischemic cardiovascular event.
• •* Cardiac arrhythmia requiring pharmacological or surgical intervention.
• •* Pericardial effusion.
• •* Pericarditis.
• •Consumes known moderate or strong inhibitors of cytochrome P450 3A isoform subfamily (CYP3A) within 14 day or 5 half-lives of the drug (whichever is shorter) before the first dose of ABBV-453.